[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:primary-sclerosing-cholangitis":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":134,"states":135},"Primary Sclerosing Cholangitis",20,18,[8,16,23,30,37,43,49,55,61,67,73,79,85,91,96,102,108,114,120,127],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07387549","A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis",[12],"Phase 3","RECRUITING","2026-08-26T02:16:59.895916Z","2026-05-13T02:55:06.699471Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06905054","Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation",[20],"Phase 2","2026-08-26T02:17:47.813245Z","2026-05-05T02:43:29.506524Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT06197308","Evaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC",[27],"Early Phase 1","2026-08-26T02:15:26.669629Z","2026-05-05T02:43:27.399263Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":35,"content_modified":36},"NCT06455280","A Study of SIPLIZUMAB in AILD and LT Patients",[34],"Phase 1","2026-08-26T02:15:02.712396Z","2026-05-05T02:43:26.978311Z",{"nct_id":38,"title":39,"phases":40,"status":13,"updated_at":41,"content_modified":42},"NCT05295680","Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.",[20],"2026-08-26T02:18:38.865010Z","2026-05-05T02:35:31.751318Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":47,"content_modified":48},"NCT05835505","Detoxification of the Liver In PSC (Dolphin)",[20],"2026-08-26T02:18:40.612983Z","2026-05-05T02:35:31.748658Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT07229911","A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)",[34],"2026-08-26T02:15:17.167444Z","2026-04-29T02:57:57.104723Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT02137668","Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin",[34],"2026-08-26T02:15:11.740957Z","2026-05-05T02:43:28.176136Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT06699121","A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC",[20],"2026-08-26T02:17:27.435233Z","2026-05-05T02:43:27.318517Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT04685200","Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach",[],"2026-08-26T02:19:03.581490Z","2026-07-05T05:32:16.797252Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT06297993","Global Prospective, Observational Cohort of Adult Patients With Primary Sclerosing Cholangitis (WIND-PSC Study)",[],"2026-08-26T02:17:25.718160Z","2026-05-13T02:55:06.434475Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT04753996","Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients",[],"2026-08-26T02:16:15.345907Z","2026-05-13T02:55:06.267754Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT04181138","Primary Sclerosing Cholangitis in Children",[],"2026-08-26T02:18:34.622081Z","2026-05-13T02:55:06.243299Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":53,"content_modified":95},"NCT03178630","MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease",[],"2026-05-13T02:55:06.108740Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT05750498","A-LiNK: Improving Outcomes in Autoimmune Liver Disease",[],"2026-08-26T02:18:14.396999Z","2026-05-13T02:55:06.375147Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT03445585","Biobank for Cholestatic Liver Diseases.",[],"2026-08-26T02:16:54.044282Z","2026-05-13T02:55:06.126362Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT03175471","MRI Based Biomarkers in Pediatric Autoimmune Liver Disease",[],"2026-08-26T02:19:21.761002Z","2026-05-13T02:55:06.109223Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT05912387","Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study",[27],"2026-08-26T02:16:50.548894Z","2026-05-05T02:43:27.254211Z",{"nct_id":121,"title":122,"phases":123,"status":124,"updated_at":125,"content_modified":126},"NCT06252610","PET\u002FMRI of Primary Sclerosing Cholangitis",[],"NOT_YET_RECRUITING","2026-08-26T02:16:42.787115Z","2026-05-13T02:55:06.429464Z",{"nct_id":128,"title":129,"phases":130,"status":131,"updated_at":132,"content_modified":133},"NCT06061341","TruGraf Liver Gene Expression Serial Test",[],"ENROLLING_BY_INVITATION","2026-08-03T02:36:24.364783Z","2026-06-16T05:54:08.096773Z",[],[136,140,144,148,151,154,158,161],{"state":137,"count":138,"slug":139},"California",7,"california",{"state":141,"count":142,"slug":143},"Minnesota",5,"minnesota",{"state":145,"count":146,"slug":147},"Ohio",4,"ohio",{"state":149,"count":146,"slug":150},"Texas","texas",{"state":152,"count":146,"slug":153},"Washington","washington",{"state":155,"count":156,"slug":157},"Colorado",3,"colorado",{"state":159,"count":156,"slug":160},"Indiana","indiana",{"state":162,"count":156,"slug":163},"Massachusetts","massachusetts"]